| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Eur J Cardiothorac Surg 2002;22:753-761
© 2002 Elsevier Science NL
a Division of Cardiovascular Surgery, Albert-Ludwigs-University of Freiburg, School of Medicine, Freiburg, Germany
b Division of Surgical Research, Albert-Ludwigs-University of Freiburg, School of Medicine, Freiburg, Germany
Received 22 April 2002; received in revised form 12 August 2002; accepted 21 August 2002.
* Corresponding author. Tel.: +49-761-270-2818; fax: +49-761-270-2550
e-mail: lutter{at}ch11.ukl.uni-freiburg.de
Objective: The purpose of this study was to determine the combined effect of transmyocardial laser revascularization (TMLR) and recombinant human basic fibroblastic growth factor (rhFGF-2) treatment in chronically ischemic hearts. Methods: To employ this porcine ischemic model, an operative severe stenosis of the left anterior descending artery (LAD) was created (first operation). One week later, the animals were studied at baseline (second operation) by analyzing perfusion (microsphere technique) and regional contractility (ultrasonic crystals). Afterwards, pigs were randomized into one of the four groups: ischemic control group (n=7), TMLR-group (n=7), FGF-2-group receiving 500 µg rhFGF-2 (n=6), and FGF-2+TMLR-group receiving TMLR with 500 µg rhFGF-2 (n=6). Twelve weeks later, the animals were re-examined (third operation) and the hearts underwent additionally histochemical and immunohistologic analysis. Results: Three months after therapy, regional myocardial blood flow (RMBF) in the LAD territory was significantly higher at rest in the FGF-2 group and FGF-2+TMLR group compared to baseline, control and TMLR group (FGF-2 group: 1.17±0.10 versus baseline 0.28±0.10, P=0.028; versus control 0.49±0.12, P=0.01; and versus TMLR 0.34±0.20, P=0.0081; FGF-2+TMLR group: 0.88±0.29 versus baseline 0.41±0.14, P=0.028; versus control 0.49±0.12, P=0.019 and versus TMLR group 0.34±0.20 ml/g per min, P=0.0032). Furthermore, the FGF-2+TMLR-group demonstrated higher RMBF values in the LAD territory under stress conditions compared to baseline (1.79±0.69 versus 0.41±0.14; P=0.028) and control (1.79±0.69 versus 0.78±0.55 ml/g per min; P=0.038) at the end of the study. In contrast to these groups, RMBF in the control and TMLR group was unchanged. After 3 months, the FGF-2- and FGF-2+TMLR-groups’ regional contractility in the LAD territory revealed an improvement at rest (FGF-2: 84.00±26.22 versus baseline: 53.76±13.49, P=0.003; FGF-2+TMLR: 104.46±28.62 versus control: 61.27±5.13; P=0.005 and versus TMLR: 59.74±41.23%; P=0.041), whereas control and TMLR animals did not show any difference. TMLR as well as FGF-2+TMLR treatment resulted in an increased number of capillaries and of arterioles in the channel area compared to untreated ischemia (P<0.005). Conclusions: In contrast to the TMLR- and control group, CO2-laser revascularization combined with the application of intramyocardial growth factor, FGF-2, significantly ameliorates perfusion at rest and stress in this model of chronic regional ischemia, whereas sole FGF-2 application showed an improvement at rest only. This was mirrored by an enhancement of regional contractility in the FGF-2+TMLR- and FGF-2-group at rest.
Key Words: Coronary disease • Transmyocardial laser revascularization • Growth factors • Arteriogenesis • Angiogenesis • Perfusion • Contractility
This article has been cited by other articles:
|
|
 |
|
  S. Villanueva, C. Cespedes, A. Gonzalez, and C. P. Vio bFGF induces an earlier expression of nephrogenic proteins after ischemic acute renal failure Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2006; 291(6): R1677 - R1687. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
